NCT04891757进行中（未招募）1 期
A Phase 1, Multicenter, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered FHD-286, as Monotherapy or Combination Therapy, in Subjects With Advanced Hematologic Malignancies
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 144
- 试验地点
- 5
- 主要终点
- Incidence of AEs, dose-limiting toxicities (DLTs), serious AEs (SAEs), AEs leading to discontinuation, and adverse events of special interest (AESIs); safety laboratory assessments
研究概览
简要总结
This Phase 1, multicenter, open-label, dose escalation study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-286 administered orally as monotherapy or combination therapy, in subjects with advanced hematologic malignancies.
详细描述
This study is primarily intended to evaluate the safety and tolerability of FHD-286 when administered orally as monotherapy or in combination with either LDAC or decitabine to subjects with R/R AML, R/R MDS, and R/R CMML not in blast crisis. In each arm of the study, successive cohorts of participants will receive increasing oral doses of FHD-286 as a single agent or in combination with LDAC or decitabine to determine the RP2D(s) in this population.
The data from this study in subjects with advanced hematologic malignancies, including safety, tolerability, PK/PD findings, and antitumor activity, will form the basis for subsequent clinical development of FHD-286.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject must be ≥16 years of age.
- •Subject must:
- •Have a confirmed diagnosis of R/R AML, R/R MDS, or R/R CMML not in blast crisis AND
- •Have received ≤4 prior lines of systemic anticancer therapy for their disease under study; subjects who have received >4 prior lines of systemic anticancer therapy for their disease under study must receive Sponsor approval. AND
- •Be an appropriate candidate for treatment with LDAC (Arm A) or decitabine (Arm B)
- •Subject or their parent or legal guardian (when applicable) must be able to understand and be willing to sign an informed consent and, when applicable, subject must sign an assent form.
- •Subject must be willing and able to comply with scheduled study visits and treatment plans.
- •Subject must be willing to undergo all study procedures unless contraindicated due to medical risk.
- •Subject must have an ECOG PS of ≤
- •Subject must have a life expectancy of ≥3 months.
- •Subject must have adequate hepatic function.
- •Subject must have adequate renal function.
- •Subject must have a WBC count ≤20×109/L; treatment with a stable dose of hydroxyurea or other cytoreductive agent (eg, cytarabine) to achieve this count is allowed.
- •Subject must have adequate cardiovascular, respiratory, and immune system function.
- •Subject must agree to abide by dietary and other considerations required during the study.
- •Subject must meet timing requirements with respect to prior therapy and surgery
- •Toxicity related to prior therapy must have returned to Grade ≤2 by CTCAE by approximately 14 days before the start of study treatment or be deemed irreversible and stable by the Investigator. Exceptions include alopecia, neuropathy, appropriately controlled endocrine toxicities, and other well-controlled stable toxicities with discussion with the Sponsor.
- •Female subjects must be:
- •postmenopausal; or
- •permanently sterile, or, if sexually active with male partners, these partners must be azoospermic; or
- •nonpregnant, nonlactating, and, if sexually active with fertile male partners, having agreed to use a highly effective method of contraception
- •Male subjects must have documented azoospermia or, if fertile and sexually active, must agree to use a highly effective method of contraception with their partners of childbearing potential
排除标准
- •Subject is unable to provide informed consent and/or to follow protocol requirements.
- •Has undergone chimeric antigen receptor T cell therapy or HSCT within 60 days of the first dose of study treatment OR
- •Has clinically significant GVHD
- •Subject has evidence (or suspicion) of extramedullary involvement, unless approved by Sponsor.
- •Subject has an immediately life-threatening, severe complication(s) of advanced myeloid malignancy, such as uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation.
- •Subject has other malignancy that may interfere with the diagnosis and/or treatment of advanced hematologic malignancies.
- •Subject has active HBV or HCV infections; Subject has known positive HIV antibody results, or AIDS-related illness.
- •Subject has an active severe infection that requires anti-infective therapy or has an unexplained temperature of >38.5°C during screening visits or on their first day of study treatment.
- •Subject has an uncontrolled intercurrent illness.
- •Subject has QTcF >470 msec or other factors that increase the risk of QTc prolongation or arrhythmic events.
- •Subject has any other medical or psychological condition, deemed by the Investigator to be likely to interfere with a subject's ability to sign informed consent/assent, cooperate, or participate in the study.
- •Subject has known allergies or hypersensitivities to:
- •All subjects: components of the FHD-286 formulation
- •Arm A: cytarabine or any of the excipients
- •Arm B: decitabine or any of the excipients
- •Subject is unable to tolerate the administration of oral medication or has GI dysfunction that would preclude adequate absorption, distribution, metabolism, or excretion of FHD-
- •Subject is receiving any other anticancer investigational agents. Investigational agents to treat non-cancer indications may be permitted with Sponsor approval.
- •Exclusion Criteria #14 was removed.
- •Subject is on medications classified as:
- •Strong CYP3A inhibitors [Exception: Triazole antifungal agents, including those classified as strong CYP3A inhibitors, are permitted.]
- •Strong CYP3A inducers
- •Sensitive CYP3A substrates with narrow TIs [Stable doses of immunosuppressant medications that are sensitive CYP3A4 substrates may be permitted with Sponsor approval.]
- •Subject is on medications with narrow TIs that are sensitive P-gp or BCRP substrates and are administered orally or on medications classified as strong inhibitors of P-gp or BCRP.
- •Administration of PPIs should be stopped or switched to another ARA 7 days before administration of FHD-
- •Subject is requiring clinically significant or increasing doses of systemic steroid therapy or any other systemic immunosuppressive medication. Local or targeted steroid and immunosuppressive therapies are acceptable. Appropriate steroid replacement to manage endocrine toxicities resulting from prior anticancer systemic therapy is permitted.
- •Subject has undergone any prior treatment with a BRG1/BRM inhibitor.
- •Subject is pregnant or breastfeeding or is planning to become pregnant within 1 year of the start of study treatment.
研究组 & 干预措施
FHD-286 in Combination with Decitabine
Experimental
FHD-286 administered orally + decitabine administered intravenously (IV)
干预措施: FHD-286 (Drug)
FHD-286 Monotherapy
Experimental
Closed to Enrollment
干预措施: FHD-286 (Drug)
FHD-286 in Combination with LDAC
Experimental
FHD-286 administered orally + LDAC administered subcutaneously
干预措施: FHD-286 (Drug)
FHD-286 in Combination with LDAC
Experimental
FHD-286 administered orally + LDAC administered subcutaneously
干预措施: Low Dose Cytarabine (Drug)
FHD-286 in Combination with Decitabine
Experimental
FHD-286 administered orally + decitabine administered intravenously (IV)
干预措施: Decitabine (Drug)
结局指标
主要结局
Incidence of AEs, dose-limiting toxicities (DLTs), serious AEs (SAEs), AEs leading to discontinuation, and adverse events of special interest (AESIs); safety laboratory assessments
时间窗: Up to 18 months
次要结局
- AML: Duration of CR + CRh(Up 18 months)
- AML: Transfusion independence rate(Up 18 months)
- MDS & CMML: Hematologic Improvement rate(Up to 18 months)
- AML: Event free survival (EFS)(Up 42 months)
- AML: Duration of CR(Up 18 months)
- AML: CR + CR with partial hematologic recovery (CRh) rate(Up 18 months)
- MDS & CMML: Duration of CR(Up to 18 months)
- MDS & CMML: Duration of PR(Up to 18 months)
- MDS & CMML: CR + PR(Up to 18 months)
- MDS & CMML: Duration of CR + PR(Up to 18 months)
- AML: Complete remission (CR) rate(Up to 18 months)
- AML: Overall survival (OS)(Up to 42 months)
- MDS: CR rate(Up to 18 months)
- MDS & CMML: Partial remission (PR) rate(Up to 18 months)
- MDS & CMML: EFS(Up to 42 months)
- MDS: OS(Up to 42 months)
- PK parameter: Area under the plasma concentration time curve (AUC)(Day 1 and day 8 of cycle 1 (each cycle is 28 days))
- Plasma concentration vs. time profiles(Day 1 and day 8 of cycle 1 (each cycle is 28 days))
研究者
研究点 (5)
Loading locations...
相似试验
已完成
1 期
Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Solid TumorsSolid TumorsNCT00942799Genzyme, a Sanofi Company87
进行中（未招募）
1 期
A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or LymphomasSolid Malignancies or LymphomasNCT05290597Innovent Biologics (Suzhou) Co. Ltd.40
已完成
1 期
Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid TumorsSolid TumorNCT01363024Genentech, Inc.24
招募中
1 期
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid TumorsAdvanced Solid TumorSubcutaneous TumorMalignant Solid TumorSolid TumorMetastatic Solid TumorMetastasis to Soft TissueNon Small Cell Lung CancerCutaneous Squamous Cell CarcinomaCutaneous TumorNCT06171750Ankyra Therapeutics, Inc97
招募中
1 期
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.CLL/SLLWaldenstrom MacroglobulinemiaDiffuse Large B Cell LymphomaMarginal Zone LymphomaHairy Cell LeukemiaMantle Cell LymphomaFollicular LymphomaNCT04775745Newave Pharmaceutical Inc60